A tetravalent rhesus-human reassortant rotavirus (RRV-TV) vaccine (4 x 10(4) plaque-forming units/dose) was evaluated for safety, immunogenicity and efficacy in a prospective, randomized, double-blind, placebo-controlled trial involving 540 Brazilian infants. Doses of vaccine or placebo were given at ages, 1, 3 and 5 months. No significant differences were noted in the occurrence of diarrhoea or vomiting in vaccine and placebo recipients following each dose. Low-grade fever occurred on days 35 in 23% of vaccinees after the first dose, but not after the second or third doses of vaccine. An IgA antibody response to rhesus rotavirus (RRV) occurred in 58% of vaccinees and 33% of placebo recipients. Neutralizing antibody responses to individual serotypes did not exceed 20% when measured by fluorescent focus reduction, but exceeded 40% when assayed by plaque reduction neutralization. There were 91 cases of rotavirus diarrhoea among the 3-dose (vaccine or placebo) recipients during two years of follow-up, 36 of them among children given the vaccine. Overall vaccine efficacy was 8% (P = 0.005) against any diarrhoea and 35% (P = 0.03) against any rotavirus diarrhoea. Protection during the first year of follow-up, when G serotype 1 rotavirus predominated, was 57% (P = 0.008), but fell to 12% in the second year. Similar results were obtained when analysis was restricted to episodes in which rotavirus was the only identified pathogen. There was a tendency for enhanced protection by vaccine against illness associated with an average of 6 or more stools per day. These results are sufficiently encouraging to warrant further studies of this vaccine in developing countries using a higher dosage in an attempt to improve its immunogenicity and efficacy.

Se evaluó la inocuidad, inmunogenicidad y eficacia de una vacuna tetravalente obtenida por recombinación genética de rotavirus aislados de monos rhesus y seres humanos (RRV-TV) (4 x 10(4) unidades formadoras de placas por dosis) en un ensayo prospectivo, aleatorio, a doble ciego y controlado con placebo que se efectuó con 540 lactantes brasileños. Se administraron dosis de vacuna o de placebo a la edad de 1, 3 y 5 meses. No se observaron diferencias significativas en la frecuencia de diarrea o vómito en los bebés de ninguno de los dos grupos después de administrar la dosis correspondiente. De 2 a 3% de los vacunados tuvieron fiebre baja los días tercero a quinto después de recibir la primera dosis, pero no después de las dosis segunda o tercera. Se observó una respuesta de anticuerpos del tipo IgA al rotavirus aislado de monos rhesus (RRV) en 58% de los vacunados y en 33% de quienes recibieron placebo. La respuesta de anticuerpos neutralizantes a cada serotipo no pasó de 20% cuando se determinó con la prueba de reducción de focos de fluorescencia, pero fue superior a 40% al medirse con la prueba de neutralización a base de reducción de placas. Se presentaron 91 casos de diarrea causada por rotavirus entre los niños que recibieron las tres dosis (de vacuna o de placebo) durante un seguimiento de 2 años, 36 de ellos en los niños vacunados. La eficacia general de la vacuna fue de 8% (P = 0,005) contra toda clase de diarrea y de 35% (P = 0,03) contra la diarrea causada por rotavirus. La protección durante el primer año de seguimiento, cuando predominó el rotavirus G del serotipo 1, fue de 57% (P = 0,008), pero se redujo a 12% en el segundo año. Se obtuvieron resultados similares al restringir el análisis a episodios en que el rotavirus fue el único agente patógeno identificado. Se observó en la vacuna una mayor tendencia a proteger contra casos de enfermedad con un promedio de seis o más deposiciones diarias. Estos resultados son lo suficientemente alentadores para justificar que en países en desarrollo se hagan otros estudios de esta vacuna con una dosis mayor para tratar de mejorar su inmunogenicidad y eficacia.

Infecção recente por herpesvírus humano tipo 6 (HHV-6) foi detectada em casos de exantema súbito envolvendo quatro crianças com idades de 10 a 24 meses, no período compreendido entre abril e agosto de 1994, em Belém, Brasil. Utilizando-se a técnica da imunofluorescência indireta, aumentos significativos (de pelo menos oito vezes) foram observados nas concentrações de anticorpos das amostras de soro, da fase aguda para as da convalescente, com títulos variando de < 1:10 / 1:80 a < 1:10 / 1:640 (pacientes 3 e 2, respectivamente). Todas as crianças apresentaram febre alta (acima de 39ºC) por três dias, seguida de exantema máculo-papular generalizado. O exame físico realizado nas crianças revelou concomitância de adenomegalia cervical e amigdalite em dois desses indivíduos.

Recent human herpesvirus 6 (HHV-6) infection was detected in cases of exanthem subitum (ES) involving four children, aged 10 to 24 months, between April and August 1994, in Belém, Brazil. By using the indirect immunofluorescence antibody assay (IFA), significant increases (at least eight times) in antibody concentrations were noted from the acute to the convalescent serum samples, with titers ranging from <1:10/1:80 to <1:10/1:640 (patients 3 and 2, respectively). All children had high fever (over 39ºC) for three days, followed by generalized, maculo-papular skin rash. A physical examination of the children also revealed concomitant, cervical lymph node swelling and tonsillar pharyngitis in two of them.

Forty-tree (31.4%) out of 137 serum samples obtained from two Indian communities living in the Amazon region were found to be positive for HTLV-I antibody, as tested by enzyme-linked immunosorbent assay (Elisa). Eighty-two sera were collected from Mekranoiti Indians, yielding 39% of positivity, whereas 11 (20.0%) or the 55 Tiriyo serum samples had antibody to HTLV-I. In addition, positive results occurred in 10 (23.2%) out of 43 sera obtained from patients living in the Belem area, who were suffering from cancer affecting different organs. Five (16.7%) out of 30 Elisa positive specimens were also shown to be positive by either Western blot analysis (WB) or indirect immunogold electron microscopy (IIG-EM).

Amostras de soro colhidas na fase aguda de doença exantemática, acomentendo duas crianças, revelaram-se positivas quanto à presença de IgM específica para o vírus B 19, através do método de rádio-imuno-ensaio por mecanismo de captura. O primeiro paciente, um menino de dois anos, apresentou erupção cutânea com seis dias de duração; o segundo foi uma menina de quatro anos de idade, irmã do primeiro paciente e que foi submetida a exame à mesma época em que se procedeu à avaliação clínica do irmão, e que exibia "rash" cutâneo que evoluía há três dias.

Acute sera from two children suffering from an illness with an erythematous rash were positive for B 19 virus specific IgM antibody, as tested by a capture radioimmunoassay. The first patient, a two year old boy, presented with a cutaneous rash of six days duration, the second was a four year old girl, sister of the first patient, who was examined at the same time and had a three day history of cutaneous rash.

Nos últimos dez anos tem sido travada uma luta com a finalidade de prevenir a transmissão de agentes infecciosos dentro de laboratórios. A grande fonte de dispersão de patógenos por meio de aerossóis, pode ser eliminada satisfatoriamente com o uso de câmaras de segurança biológica. Regras gerais e específicas de biossegurança devem ser cumpridas por todos os usuários de laboratórios que manuseiam patógenos ou materiais potencialmente contaminantes e, eventualmente, avaliados por um comitê de biossegurança independente. O surgimento da síndrome de imunodeficiência adquirida deve servir.como fator de estímulo à adoção de normas eficazes de segurança laboratorial.

The occurrence of laboratory-acquired infections have elicited in the last ten years an intense interest in methods and procedures for the safe handling of microbiological material. The major laboratory safety problem is aerial transmission, however, protection against airborne hazards is efficiently achieved by the use of microbiological safety cabinets. Biosafety rules should be strictly followed by all members of a laboratory. Evaluation of these procedures should be effectively performed by an independent biosafety committee. The/ upsurge of AIDS should stimulate the adoption of safe working procedures in the laboratory.